Refeyn
This company was started by Philip Kukura to commercialize iSCAT devices. I am not sure about their internal structure, but it has been active since 2018.
In Nov 2020 they got a 30MU$ round.
Their devices are sold for 170k€, installation and 1-day training are 2300U$, and they have a range of consumables (like clean coverslips).
As far as I understand, their goal since the inception of the company is the traditional Oxford path: get acquired ASAP. After a 30M round, I see this a bit less likely in the short term. In order to grow to a ~300M valuation, they'll have to achieve sales of around 200 devices a year and show no stagnation.
That may be the deal with Illumion, opening new business lines without sacrificing their own capital and brand in the bio sector.
Backlinks
These are the other notes that link to this one.
Comment
